Filing Details
- Accession Number:
- 0001179110-22-001832
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-01 18:08:44
- Reporting Period:
- 2022-02-25
- Accepted Time:
- 2022-03-01 18:08:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1551152 | Abbvie Inc. | ABBV | Pharmaceutical Preparations (2834) | 320375147 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1761675 | Ryan Jeffrey Stewart | 1 North Waukegan Road North Chicago IL 60064 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 Par Value | Disposition | 2022-02-25 | 17,093 | $149.54 | 82,429 | No | 4 | F | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2022-03-01 | 6,229 | $147.43 | 76,200 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2022-03-01 | 12,659 | $148.49 | 63,541 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value | Disposition | 2022-03-01 | 2,600 | $149.04 | 60,941 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock, $0.01 Par Value | 1,338 | Indirect | By spouse in trust |
Footnotes
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.86 to $147.85 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.86 to $148.85 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.86 to $149.48 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reporting person disclaims beneficial ownership of all securities held by his spouse.
Billionaire Hedge Funds
